Lindsay Kilburn

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 472 citations · Full text

Neuro-oncology, Tumoral Pathology, Pediatric Brain Tumors +12

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy

Eshini Panditharatna, Lindsay Kilburn, Mariam Aboian et al. · Clinical Cancer Research · 2018 · 184 citations · Full text

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · Neuro-Oncology · 2021 · 147 citations · Full text

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford et al. · Nature Medicine · 2023 · 146 citations · Full text

Long‐term efficacy and toxicity of bevacizumab‐based therapy in children with recurrent low‐grade gliomas

Eugene Hwang, Regina I. Jakacki, Michael J. Fisher et al. · Pediatric Blood & Cancer · 2012 · 143 citations